All relevant data are within the paper and its Supporting Information files.

Introduction {#sec005}
============

Septic shock and severe sepsis are a grave consequence of infection. Septic shock accounts for about 9% of admissions, and is the most common cause of death in intensive care units (ICUs) \[[@pone.0129305.ref001],[@pone.0129305.ref002]\]. The mortality rate reported is 40 to 60% \[[@pone.0129305.ref001],[@pone.0129305.ref003]\]. Septic shock is defined by the ACCP/SCCM as the need for vasopressors to reverse sepsis-induced hypotension \[[@pone.0129305.ref004]\]. The concept of \"early goal directed therapy\" was developed in order to set early hemodynamic goals. The goals include central venous or mixed venous saturation (ScvO~2~) higher than 70%, mean arterial pressure (MAP) ≥ 65 mmHg, central venous pressure (CVP) \> 8--12 mmHg, and urine output \> 0.5 ml/kg/hr within 6 hours of initiation of therapy \[[@pone.0129305.ref005]\]. Later the concept of lactate clearance was added to the goals as an alternative or addition to the ScvO~2~ \[[@pone.0129305.ref006]\]. Thus, hemodynamic outcomes are regarded as surrogate markers for survival, the ultimate goal of treatment.

No study to date has demonstrated a statistically significant survival benefit of one vasopressor over another. Therefore, the choice of vasopressor in septic shock is rather empiric. The Surviving Sepsis Campaign recommends norepinephrine or dopamine as the first-choice vasopressor agent followed by epinephrine in patients who respond poorly to dopamine or norepinephrine \[[@pone.0129305.ref007],[@pone.0129305.ref008]\].

In this systematic review we aimed to examine the evidence on the relative clinical, hemodynamics and safety of any vasopressors in the treatment of septic shock, in order to guide future trials and treatment guidelines.

Methods {#sec006}
=======

Inclusion criteria {#sec007}
------------------

Randomized controlled trials (RCTs) and randomized crossover trials regardless of publication status were included. We included trials assessing adult patients with septic shock and sepsis with multiple organ dysfunction syndrome diagnosed using established criteria \[[@pone.0129305.ref004]\], or an accepted definition of severe sepsis and end organ damage caused by hypoperfusion. In studies that recruited patients with shock due to many causes, we extracted data for septic patients where possible. The intervention assessed was vasopressor versus a different vasopressor, a combination of vasopressors, placebo or no vasopressor. The following vasopressors were included: dopamine, norepinephrine, epinephrine, phenylephrine, vasopressin and terlipressin.

We regarded vasopressin and terlipressin as non-adrenergic vasopressors. Trials that added open-label vasopressor(s) were included if it was applied to both arms of intervention. Studies comparing interventions limited to inotrope agents were excluded. We excluded studies that assessed different dosages or schedules of the same vasopressors.

Outcomes assessed {#sec008}
-----------------

The primary outcome was all-cause mortality at 28 days following randomization, or when lacking these data, all-cause mortality as reported by the authors. Secondary outcomes included length of ICU stay and / or hospital stay in patients discharged alive; ventilator free days; vasopressor free days; hemodynamic profiles of patients at the first hour (or first measuring point), and at the 6^th^ hour (or second measuring point); and adverse events (AEs) (major AEs, arrhythmias, myocardial infarction, stroke, internal organ ischemic damage, and local extravasation or skin necrosis). The hemodynamic profile consisted of CVP, MAP, ScvO~2~, urinary output, blood lactate levels, cardiac index (CIX), systemic vascular resistance index (SVRI), heart rate, and oxygen delivery index (VIO~2~); we also collected measurements of splanchnic blood flow, oxygen delivery, oxygen consumption and visceral CO~2~ difference as measured by catheter sampling or tonometry. In studies that allowed crossover between arms, we included data regarding the first randomization only, if available. Mortality was not extracted from crossover studies. Outcome measures were collected on an intention-to-treat basis. Where such data was not presented, per-protocol results were used. We also compared results for adrenergic vasopressors versus non-adrenergic vasopressors.

Search methods {#sec009}
--------------

We searched MEDLINE, CENTRAL, LILACS and conference proceedings (International Symposium on Intensive Care and Emergency Medicine), up to June 2014. We also hand-searched all references of included studies, and previous meta-analyses for more trials. The words \"vasopressor\" and vasopressor names and their MESH terms were crossed with the terms \"hypotension\", \"circulatory failure\", \"shock\", \"sepsis\" or \"bacteremia\" and with the Cochrane highly sensitive filter for RCTs \[[@pone.0129305.ref009]\]. No language restrictions were used. Authors were contacted to complement data by e-mail and phone calls.

Data collection {#sec010}
---------------

Two reviewers independently inspected each reference identified by the search, scanned full-texts of relevant studies, applied the inclusion criteria and extracted the data. Disagreements in data extraction were resolved by discussion with a third reviewer. Risk of bias was assessed in duplicate using domain-based evaluation, classifying studies primarily according to the risk of non-random allocation of patients to the intervention arm, i.e. allocation concealment and sequence generation. These were graded as adequate, unclear and inadequate as recommended in The Cochrane Handbook \[[@pone.0129305.ref009]\]. Additional domains assessed included blinding, incomplete outcome data reporting, ethics committee, patient consent and industrial sponsorship.

Data analysis {#sec011}
-------------

For binary data, individual study results are expressed as RR with 95% CI. For continuous outcomes we extracted end-value means with standard deviations (SD), as data for change from baseline was unavailable. In studies that reported median with interquartile ranges, we converted the reported values to means assuming a normal distribution \[[@pone.0129305.ref010]\]. RRs and mean differences were pooled using a fixed effect model (Mantel-Haenszel method) (Review Manager \[RevMan\], version 5.3 for Windows, The Cochrane Collaboration, Oxford, UK). Heterogeneity was defined by a chi-square test of heterogeneity \<0.1 or an I^2^ measure of inconsistency \>40%. If significant heterogeneity was identified, we used random effect model (REM). We explored potential sources of heterogeneity: trials published before versus after the year 2004 (surviving sepsis campaign), trials conducted in developed versus developing countries, and the adequacy of allocation concealment and blinding

Results {#sec012}
=======

The search yielded 2,380 publications of which 61 were potentially relevant. Thirty-six studies were excluded ([Fig 1](#pone.0129305.g001){ref-type="fig"}), and 7 studies were added from reference hand searching. Altogether, 32 studies \[[@pone.0129305.ref011]--[@pone.0129305.ref042]\] were included (all published in peer-review journals). The trials were published in the years 1989--2012 and recruited 3,544 patients (median 50 patients, [Table 1](#pone.0129305.t001){ref-type="table"} for trials' characteristics). Five trials were crossover \[[@pone.0129305.ref016]--[@pone.0129305.ref018],[@pone.0129305.ref037],[@pone.0129305.ref041]\] and the remaining were parallel RCTs. The comparisons assessed in included trials are summarized in [Fig 2](#pone.0129305.g002){ref-type="fig"}. The main comparisons were between norepinephrine and dopamine (14 trials, including 2 crossover trials) and norepinephrine and epinephrine (7 trials including 3 crossover trials). One trial compared vasopressin to placebo \[[@pone.0129305.ref024]\]; Additional open-label vasopressors could be added to both study arms equally in 16/32 trials ([Fig 2](#pone.0129305.g002){ref-type="fig"}). Eight trials were designed to measure clinical endpoints as the primary outcome, while 26 trials, including all crossover trials, measured hemodynamic data (crossover time at 45--220 minutes). The follow up duration was not stated in 21/32 trials; When stated, follow-up ranged from length of the ICU stay (3 trials) to 90 days (median 28 days). The common sources of infection were respiratory (34.6% of included patients) and intra-abdominal (25.1%). Steroid administration was reported in 5 studies, and given to 31--100% of all patients (median 74%), ([Table 1](#pone.0129305.t001){ref-type="table"}). The amount of fluids that was given for the resuscitation was reported in 7/32 trials and varied considerably (median 150 ml/hr, range 45--300 ml/hr). Another 10 trials reported a protocol based fluid resuscitation and titration by CIX. The weighted mean all-cause mortality was 45.0% (SD 16.2%, range 16.7--88.7%) and was not significantly correlated with publication year (Spearman's rho -0.260, p = 0.24, 32 studies, [Table 1](#pone.0129305.t001){ref-type="table"}).

![Study flow chart.](pone.0129305.g001){#pone.0129305.g001}

![Vasopressors arms comparisons.](pone.0129305.g002){#pone.0129305.g002}

10.1371/journal.pone.0129305.t001

###### Trials characteristics.

![](pone.0129305.t001){#pone.0129305.t001g}

  Study ID                                    Country, SC / MC[^1^](#t001fn002){ref-type="table-fn"}   Intervention                            Primary outcome   N patients   Mean age   Mean MAP at baseline (mmHg)   Mean lactate at baseline (mmol/l)   Mean cardiac index (l/min/m^2^)   APACHE II / SAPS-2 / SOFA score at baseline [^2^](#t001fn003){ref-type="table-fn"}   28 days, All-cause mortality   Mortality in longest follow up, follow-up duration
  ------------------------------------------- -------------------------------------------------------- --------------------------------------- ----------------- ------------ ---------- ----------------------------- ----------------------------------- --------------------------------- ------------------------------------------------------------------------------------ ------------------------------ ----------------------------------------------------
  Agrawal 2011 \[[@pone.0129305.ref011]\]                                                                                                      hemodynamic                                                                                                                                                                                                                                                       NS
                                              India, SC                                                Norepinephrine                                            25           52         NS                            NS                                  5.45                              25 (A)                                                                               NS                             NS
                                                                                                       Dopamine                                                  25           54         NS                            NS                                  5.28                              24 (A)                                                                               NS                             NS
  Albanese 2005 \[[@pone.0129305.ref012]\]                                                                                                     hemodynamic                                                                                                                                                                                                                                                       NS
                                              France, SC                                               Norepinephrine                                            10           65         54                            NS                                  5.1                               29 (A)                                                                               40%                            NS
                                                                                                       Terlipressin                                              10           66         54                            NS                                  5.0                               28 (A)                                                                               50%                            NS
  Annane 2007 \[[@pone.0129305.ref013]\]                                                                                                       survival                                                                                                                                                                                                                                                          90 days
                                              France, MC                                               Norepinephrine + Dobutamine                               169          60         68                            3.3                                 NS                                52 (S)                                                                               34%                            50%
                                                                                                       Epinephrine                                               161          65         70                            2.9                                 NS                                54 (S)                                                                               39%                            52%
  Chen 2012 \[[@pone.0129305.ref014]\]                                                                                                         hemodynamic                                                                                                                                                                                                                                                       NS
                                              China, SC                                                Norepinephrine                                            40           NS         NS                            NS                                  NS                                NS                                                                                   22%                            NS
                                                                                                       Dopamine                                                  40           NS         NS                            NS                                  NS                                NS                                                                                   27%                            NS
  De Backer 2003 \[[@pone.0129305.ref016]\]                                                                                                    hemodynamic                                                                                                                                                                                                                        80%                            NS
                                              Belgium, SC                                              Norepinephrine crossover                                  5            NS         NS                            NS                                  NS                                19 (A)                                                                                                              
                                                                                                       Epinephrine crossover                                     5            NS         NS                            NS                                  NS                                19 (A)                                                                                                              
  De Backer 2010 \[[@pone.0129305.ref015]\]                                                                                                    survival                                                                                                                                                                                                                                                          12 months
                                              Belgium, Austria, Spain, MC                              Norepinephrine                                            502          NS         NS                            NS                                  NS                                NS                                                                                   49%                            NS
                                                                                                       Dopamine                                                  542          NS         NS                            NS                                  NS                                NS                                                                                   53%                            NS
  Duranteau 1999 \[[@pone.0129305.ref017]\]                                                                                                    hemodynamic                                                                                                                                                                                                                        58%                            NS, NS
                                              France, SC                                               Norepinephrine crossover                                  4            54         NS                            NS                                  NS                                NS                                                                                                                  
                                                                                                       Norepinephrine + Dobutamine crossover                     4            54         NS                            NS                                  NS                                NS                                                                                                                  
                                                                                                       Epinephrine crossover                                     4            54         NS                            NS                                  NS                                NS                                                                                                                  
  Guérin 2005 \[[@pone.0129305.ref018]\]                                                                                                       hemodynamic                                                                                                                                                                                                                        16%                            NS, NS
                                              France, SC                                               Norepinephrine crossover                                  6            40         56.8                          2.3                                 4.07                              14 (A)                                                                                                              
                                                                                                       Dopamine crossover                                        6            40         56.8                          2.3                                 4.07                              14 (A)                                                                                                              
  High 2008\[[@pone.0129305.ref019]\]                                                                                                          hemodynamic                    56                                                                                                                                                                                                                                 NS
                                              China, SC                                                Norepinephrine                                            23                      NS                            NS                                  NS                                NS                                                                                   39%                            NS
                                                                                                       Dopamine                                                  21                      NS                            NS                                  NS                                NS                                                                                   38%                            NS
  Jain 2010 \[[@pone.0129305.ref020]\]                                                                                                         hemodynamic                                                                                                                                                                                                                                                       NS
                                              India, SC                                                Norepinephrine                                            27           42         68                            NS                                  5.0                               17.6 (A)                                                                             55%                            NS
                                                                                                       Phenylephrine                                             27           45         69                            NS                                  4.8                               19.1 (A)                                                                             59%                            NS
  Lauzier 2006 \[[@pone.0129305.ref021]\]                                                                                                      hemodynamic                                                                                                                                                                                                                                                       NS
                                              France, Canada, MC                                       Norepinephrine                                            10           58.1       68                            3.33                                4.4                               23.5 (A)                                                                             33%                            NS
                                                                                                       Vasopressin                                               13           51.2       72                            2.87                                4.6                               22.8 (A)                                                                             23%                            NS
  Levy 1997\[[@pone.0129305.ref022]\]                                                                                                          hemodynamic                                                                                                                                                                                                                                                       NS
                                              France, SC                                               Norepinephrine + Dobutamine                               15           56         60                            3.1                                 4.0                               25.6 (A)                                                                             53%                            NS
                                                                                                       Epinephrine                                               15           54         60                            3.1                                 4.0                               24.5 (A)                                                                             60%                            NS
  Liu 2010 \[[@pone.0129305.ref023]\]                                                                                                          hemodynamic                    43                                                                                                                                                                                                                                 NS
                                              China, SC                                                Norepinephrine                                            25                      NS                            4.9                                 NS                                16 (A)                                                                               32%                            NS
                                                                                                       Dopamine                                                  25                      NS                            4.6                                 NS                                17 (A)                                                                               48%                            NS
  Malay 1999 \[[@pone.0129305.ref024]\]                                                                                                        hemodynamic                                                                                                                                                                                                                                                       NS
                                              US, SC                                                   Placebo                                                   5            56         64                            NS                                  5.6                               26 (A)                                                                               40%                            NS
                                                                                                       Vasopressin                                               5            53         66                            NS                                  4.3                               27 (A)                                                                               0                              NS
  Marik 1994 \[[@pone.0129305.ref025]\]                                                                                                        hemodynamic                                                                                                                                                                                                                                                       NS
                                              US, SC                                                   Norepinephrine                                            10           46         65                            1.8                                 4.2                               18 (A)                                                                               50%                            NS
                                                                                                       Dopamine                                                  10           46         63                            2.2                                 4.2                               17 (A)                                                                               60%                            NS
  Marthur 2007 \[[@pone.0129305.ref026]\]                                                                                                      hemodynamic                                                                                                                                                                                                                                                       NS
                                              India, SC                                                Norepinephrine                                            25           52         NS                            NS                                  5.4                               25.6 (A)                                                                             56%                            NS
                                                                                                       Dopamine                                                  25           54         NS                            NS                                  5.2                               24.5 (A)                                                                             76%                            NS
  Martin 1993 \[[@pone.0129305.ref027]\]                                                                                                       hemodynamic                                                                                                                                                                                                                                                       NS
                                              France, SC                                               Norepinephrine                                            16           52         54                            4.8                                 5.4                               31 (A)                                                                               43%                            NS
                                                                                                       Dopamine                                                  16           53         53                            4.8                                 5.3                               30 (A)                                                                               62%                            NS
  Morelli 2008 \[[@pone.0129305.ref030]\]                                                                                                      hemodynamic                                                                                                                                                                                                                                                       NS
                                              Italy, SC                                                Norepinephrine                                            16           70         55                            2.8                                 4.4                               55 (S)                                                                               56%                            NS
                                                                                                       Phenylephrine                                             16           70         54                            2.8                                 4.3                               57 (S)                                                                               62%                            NS
  Morelli 2009 \[[@pone.0129305.ref029]\]                                                                                                      hemodynamic                                                                                                                                                                                                                                                       NS
                                              Italy, SC                                                Norepinephrine                                            15           64         54                            3.1                                 4.0                               58 (S)                                                                               66%                            NS
                                                                                                       Vasopressin                                               15           66         53                            3.0                                 4.0                               60 (S)                                                                               53%                            NS
                                                                                                       Terlipressin                                              15           67         53                            3.1                                 4.0                               62 (S)                                                                               46%                            
  Morelli 2011\[[@pone.0129305.ref028]\]                                                                                                       hemodynamic                                                                                                                                                                                                                                                       NS
                                              Italy, SC                                                Norepinephrine                                            20           66         71                            2.5                                 4.0                               54 (S)                                                                               NS                             NS
                                                                                                       Vasopressin                                               20           61         72                            2.3                                 4.0                               53 (S)                                                                               NS                             NS
                                                                                                       Terlipressin                                              20           65         71                            1.8                                 3.8                               50 (S)                                                                               NS                             NS
  Myburgh 2008 \[[@pone.0129305.ref031]\]                                                                                                      hemodynamic                                                                                                                                                                                                                                                       90 days
                                              Australia, MC                                            Norepinephrine                                            82           60         66                            2.4                                 NS                                22.7 (A)                                                                             29%                            36.5%
                                                                                                       Epinephrine                                               76           58         65                            2.7                                 NS                                23.4 (A)                                                                             22%                            31%
  Patel 2002 \[[@pone.0129305.ref032]\]                                                                                                        hemodynamic                                                                                                                                                                                                                                                       NS
                                              Canada, SC                                               Norepinephrine                                            11           68         68                            NS                                  5.0                               24 (A)                                                                               NS                             NS
                                                                                                       Vasopressin                                               13           68         69                            NS                                  4.8                               22 (A)                                                                               NS                             NS
  Patel 2010 \[[@pone.0129305.ref033]\]                                                                                                        survival                                                                                                                                                                                                                                                          28 days
                                              US, MC                                                   Norepinephrine                                            118          NS         NS                            NS                                  NS                                27 (A)                                                                               43%                            43%
                                                                                                       Dopamine                                                  134          NS         NS                            NS                                  NS                                28 (A)                                                                               50%                            50%
  Plotkin 2007 \[[@pone.0129305.ref034]\]                                                                                                      survival                                                                                                                                                                                                                                                          NS
                                              Russia, SC                                               Dopamine                                                  33           40         NS                            3.2                                 2.8                               24 (A)                                                                               90%                            NS
                                                                                                       Terlipressin                                              41           40         NS                            3.6                                 2.8                               24 (A)                                                                               73%                            NS
  Ruokonen 1993 \[[@pone.0129305.ref035]\]                                                                                                     hemodynamic                                                                                                                                                                                                                                                       NS
                                              Finland, SC                                              Norepinephrine                                            5            44         55                            2.1                                 4.4                               13.3 (A)                                                                             80%                            NS
                                                                                                       Dopamine                                                  5            46         59                            1.3                                 4.1                               13.3 (A)                                                                             60%                            NS
  Russell 2008 \[[@pone.0129305.ref036]\]                                                                                                      survival                                                                                                                                                                                                                                                          90 days
                                              US, Australia, Canada, MC                                Norepinephrine                                            395          61         73                            3.5                                 NS                                27.1 (A)                                                                             39%                            49%
                                                                                                       Vasopressin                                               404          59         72                            3.5                                 NS                                27 (A)                                                                               35%                            44%
  Schreuder 1989 \[[@pone.0129305.ref037]\]                                                                                                    hemodynamic                                                                                                                                                                                                                        80%                            NS, NS
                                              The Netherlands, SC                                      Norepinephrine crossover                                  5            57         56                            2.3                                 4.07                              NS                                                                                                                  
                                                                                                       Dopamine crossover                                        5            57         56                            2.3                                 4.07                              NS                                                                                                                  
  Seguin 2002 \[[@pone.0129305.ref038]\]                                                                                                       hemodynamic                                                                                                                                                                                                                                                       NS
                                              France, MC                                               Norepinephrine + Dobutamine                               11           70         51                            5.3                                 3.0                               62 (S)                                                                               45%                            NS
                                                                                                       Epinephrine                                               11           65         54                            3.9                                 3.2                               57 (S)                                                                               36%                            NS
  Svoboda 2012 \[[@pone.0129305.ref039]\]                                                                                                      hemodynamic                                                                                                                                                                                                                                                       90 days
                                              Czech Republic, SC                                       Norepinephrine                                            13           75         71                            NS                                  NS                                18 (SO)                                                                              76%                            92%
                                                                                                       Terlipressin                                              17           70         74                            NS                                  NS                                18 (SO)                                                                              94%                            94%
  Wu 2010 \[[@pone.0129305.ref040]\]                                                                                                           hemodynamic                    55                                                                                                                                                                                                                                 NS
                                              China, SC                                                Norepinephrine                                            23                      52                            5.9                                 4.4                               22 (A)                                                                               30%                            NS
                                                                                                       Dopamine                                                  23                      50                            6.1                                 4.3                               21 (A)                                                                               39%                            NS
  Zhou 2002 \[[@pone.0129305.ref041]\]                                                                                                         hemodynamic                                                                                                                                                                                                                        58%                            NS
                                              China, SC                                                Norepinephrine crossover                                  4            NS         60                            2.6                                 4.9                               22 (A)                                                                                                              NS
                                                                                                       Norepinephrine + Dobutamine crossover                     4            NS         60                            2.6                                 4.9                               22 (A)                                                                                                              NS
                                                                                                       Epinephrine crossover                                     4            NS         60                            2.6                                 4.9                               22 (A)                                                                                                              NS
  Zhuangyu 2011 \[[@pone.0129305.ref042]\]                                                                                                     survival                                                                                                                                                                                                                                                          NS
                                              China, SC                                                Norepinephrine                                            45           54         71                            NS                                  NS                                24 (A)                                                                               28%                            NS
                                                                                                       Dopamine                                                  45           55         74                            NS                                  NS                                25 (A)                                                                               31%                            NS

All results present in mean (or median if not reported).

^1^ MC--multicenter, SC--single-center.

^2^ (A)---APACHE II, (S)--SAPS-2, (SO)--SOFA score.

Risk of bias assessment {#sec013}
-----------------------

Risk of bias assessment is detailed in [Table 2](#pone.0129305.t002){ref-type="table"}. Low risk sequence generation and allocation concealment were reported in 16/32 (50%) and 13/32 (40.6%) trials, respectively. One study was triple blinded \[[@pone.0129305.ref015]\], 8 trials were double blinded \[[@pone.0129305.ref013], [@pone.0129305.ref024], [@pone.0129305.ref026], [@pone.0129305.ref027], [@pone.0129305.ref030]--[@pone.0129305.ref032], [@pone.0129305.ref036]\], 2 were single blinded \[[@pone.0129305.ref020], [@pone.0129305.ref034]\] and the others were open-labeled or not stated. Results were analysed by intention-to-treat in all trials. Informed consent and ethical committee approval were described in 26/32 and 25/32 trials, respectively. Industrial sponsorship was stated in one trial \[[@pone.0129305.ref039]\]. Definitions of sepsis and septic shock for inclusion criteria, were described as suggested by the ACCP/SCCM consensus or similar by 30/32 (93.7%) of all studies.

10.1371/journal.pone.0129305.t002

###### Risk of bias assessment.

![](pone.0129305.t002){#pone.0129305.t002g}

  Study ID                                    Sequence generation   Allocation concealment   Blinding   Ethical committee / informed consent   ITT analysis of primary outcome   Incomplete data reporting   Valid definition of septic shock
  ------------------------------------------- --------------------- ------------------------ ---------- -------------------------------------- --------------------------------- --------------------------- ----------------------------------
  Agrawal 2011 \[[@pone.0129305.ref011]\]     Unclear               Unclear                  Open       Yes / Yes                              Yes                               Unclear                     Yes
  Albanese 2005 \[[@pone.0129305.ref012]\]    Low                   Unclear                  Open       Yes / Yes                              Yes                               Unclear                     Yes
  Annane 2007 \[[@pone.0129305.ref013]\]      Low                   Low                      Double     Yes / Yes                              Yes                               No                          Yes
  Chen 2012 \[[@pone.0129305.ref014]\]        Unclear               Unclear                  Open       Unclear / Unclear                      Yes                               Unclear                     Yes
  De Backer 2003 \[[@pone.0129305.ref016]\]   Unclear               Unclear                  Open       Yes / Yes                              Yes                               Unclear                     Yes
  De Backer 2010 \[[@pone.0129305.ref015]\]   Low                   Low                      Triple     Yes / Yes                              Yes                               No                          Yes
  Duranteau 1999 \[[@pone.0129305.ref017]\]   Unclear               Unclear                  Open       Yes / Yes                              Yes                               Unclear                     Yes
  Guérin 2005 \[[@pone.0129305.ref018]\]      Unclear               Unclear                  Open       Yes / Yes                              Yes                               Unclear                     Yes
  High 2008\[[@pone.0129305.ref019]\]         Unclear               Unclear                  Open       Unclear / Unclear                      Yes                               Unclear                     No
  Jain 2010 \[[@pone.0129305.ref020]\]        Low                   Low                      Single     Yes / Yes                              Yes                               Unclear                     Yes
  Lauzier 2006 \[[@pone.0129305.ref021]\]     Low                   Low                      Open       Yes / Yes                              Yes                               Unclear                     Yes
  Levy 1997\[[@pone.0129305.ref022]\]         Low                   Low                      Open       Yes / Yes                              Yes                               Unclear                     Yes
  Liu 2010 \[[@pone.0129305.ref023]\]         Unclear               Unclear                  Open       Unclear / Unclear                      Yes                               Unclear                     Yes
  Malay 1999 \[[@pone.0129305.ref024]\]       Low                   Unclear                  Double     Yes / Yes                              Yes                               Unclear                     Yes
  Marik 1994 \[[@pone.0129305.ref025]\]       Low                   Low                      Open       Yes / Unclear                          Yes                               Unclear                     Yes
  Marthur 2007 \[[@pone.0129305.ref026]\]     Unclear               Unclear                  Double     Yes / Yes                              Yes                               Unclear                     Yes
  Martin 1993 \[[@pone.0129305.ref027]\]      Low                   Low                      Double     Yes / Yes                              Yes                               Unclear                     Yes
  Morelli 2008 \[[@pone.0129305.ref030]\]     Low                   Low                      Double     Yes / Yes                              Yes                               No                          Yes
  Morelli 2009 \[[@pone.0129305.ref029]\]     Low                   Low                      Open       Yes / Yes                              Yes                               No                          Yes
  Morelli 2011\[[@pone.0129305.ref028]\]      Unclear               Unclear                  Open       Yes / Yes                              Yes                               Unclear                     Yes
  Myburgh 2008 \[[@pone.0129305.ref031]\]     Low                   Low                      Double     Yes / Yes                              Yes                               No                          Yes
  Patel 2002 \[[@pone.0129305.ref032]\]       Low                   Unclear                  Double     Yes / Yes                              Yes                               Unclear                     Yes
  Patel 2010 \[[@pone.0129305.ref033]\]       High                  Unclear                  Open       Yes / Yes                              Yes                               No                          Yes
  Plotkin 2007 \[[@pone.0129305.ref034]\]     Unclear               Unclear                  Single     Unclear / Unclear                      Yes                               Unclear                     Yes
  Ruokonen 1993 \[[@pone.0129305.ref035]\]    Unclear               Unclear                  Open       Yes / Yes                              Yes                               Unclear                     Yes
  Russell 2008 \[[@pone.0129305.ref036]\]     Low                   Low                      Double     Yes / Yes                              Yes                               No                          Yes
  Schreuder 1989 \[[@pone.0129305.ref037]\]   Unclear               Unclear                  Open       Yes / Yes                              Yes                               Unclear                     Yes
  Seguin 2002 \[[@pone.0129305.ref038]\]      Low                   Low                      Open       Yes / Yes                              Yes                               Unclear                     Yes
  Svoboda 2012 \[[@pone.0129305.ref039]\]     Low                   Low                      Open       Yes / Yes                              Yes                               Unclear                     Yes
  Wu 2010 \[[@pone.0129305.ref040]\]          Unclear               Unclear                  Open       Unclear / Unclear                      Yes                               Unclear                     Yes
  Zhou 2002 \[[@pone.0129305.ref041]\]        Unclear               Unclear                  Open       Yes / Yes                              Yes                               Unclear                     Yes
  Zhuangyu 2011 \[[@pone.0129305.ref042]\]    Unclear               Unclear                  Open       Unclear / Unclear                      Yes                               Unclear                     No

Primary outcome {#sec014}
---------------

Mortality was reported in eleven trials that compared norepinephrine to dopamine. Funnel plot did not detect high risk of publication bias ([S1 Fig](#pone.0129305.s001){ref-type="supplementary-material"}). Norepinephrine was associated with reduced all-cause mortality (RR 0.89, 95% CI 0.81--0.98, I^2^ = 0%), corresponding to an absolute risk reduction of 11% and number needed to treat of 9 ([Fig 3](#pone.0129305.g003){ref-type="fig"}). Excluding De Backer\'s study from 2010 \[[@pone.0129305.ref015]\] which contributed 64% of the weight, did not alter the results, RR 0.84 (95% CI 0.70--0.99, I^2^ = 0%, n = 10), as the exclusion of other trials. Sensitivity analysis restricted to trials from the developed world, trials published after 2004, trials with adequate allocation concealment and generation and blinding did not alter this result. Analysis based on trials whose primary outcome was clinical \[[@pone.0129305.ref015], [@pone.0129305.ref033], [@pone.0129305.ref042]\] revealed the same trend for reduced mortality with norepinephrine that was not statistically significant (RR 0.91 95% CI 0.82--1.02).

![Norepinephrine versus dopamine, 28 days all-cause mortality.](pone.0129305.g003){#pone.0129305.g003}

There was no statistically significant mortality benefit with norepinephrine over epinephrine (RR 0.96, 95% CI 0.77--1.21, I^2^ = 0%, n = 4). Excluding one trial that did not add dobutamine to norepinephrine did not alter the results (RR 0.89, 95% CI 0.69--1.14, I^2^ = 0%, n = 3). There was no statistically significant mortality benefit with norepinephrine over vasopressin / terlipressin RR 1.07 (95% CI 0.91--1.26, I^2^ = 0%, n = 5), and over phenylephrine RR 0.92 (95% CI 0.64--1.32, I^2^ = 0%, n = 2). Results for the comparison of dopamine to terlipressin, and vasopressin to placebo were not pooled (one trial for each comparison, no change in mortality ratio within each trial). When compared to all other treatments, norepinephrine and vasopressin were not associated with a benefit in mortality (RR 0.96, 95% CI 0.86--1.04, I^2^ = 0%, n = 16, and RR 1.01, 95% CI 0.88--1.15, I^2^ = 14%, n = 8, respectively). Comparing adrenergic to non-adrenergic vasopressors resulted in no benefit in mortality for either groups (RR 1.17, 95% CI 0.90--1.51, I^2^ = 10%, n = 7). The pre-defined sensitivity analyses did not alter these results.

Secondary outcomes {#sec015}
------------------

### Length of ICU stay, days free of vasopressors / ventilation and AEs {#sec016}

ICU stay was reported in 6 trials, all compared norepinephrine to other vasopressors (median 13 days range 7--25). No advantage was found for the use of norepinephrine over other vasopressors (mean difference 1.01 days, 95% CI -0.65--2.66, I^2^ = 0%) ([S2 Fig](#pone.0129305.s002){ref-type="supplementary-material"}). Hospital stay in patients discharged alive was reported in 3 trials, all compare norepinephrine to other vasopressors (median 15 days, range 7--52). No advantage was found for the use of norepinephrine. Only two trials reported data for days free of ventilation and days free of vasopressor support, therefore we did not pool these results. Eight trials reported major AEs, which included life threatening tachyarrhythmias (37 events, 3 trials), any arrhythmias (475 events, 7 trials), myocardial ischemia or arrest (80 events, 5 trials), stroke (13 events, 2 trials), internal organ or limb ischemia (126 events, 4 trials) and other (9 events, 1 trial). Major AEs were decreased with norepinephrine in comparison to dopamine, RR 0.34 (95% CI 0.14--0.84, I^2^ = 0%, n = 3, [Fig 4](#pone.0129305.g004){ref-type="fig"}). Arrhythmias, were significantly decreased with norepinephrine compared to dopamine, RR 0.48 (95% CI 0.40--0.58, I^2^ = 30%, n = 4, [Fig 4](#pone.0129305.g004){ref-type="fig"}). Compared with vasopressin / terlipressin, norepinephrine was not associated with a statistically significant change in major AEs and arrhythmias. Due to lack of reported data, we did not pool other AEs separately. Data for AEs with epinephrine and phenylephrine was sparse and did not allow pooled meta-analysis.

![a. Norepinephrine versus dopamine, major adverse events. b. Norepinephrine versus dopamine, cardiac arrhythmias.](pone.0129305.g004){#pone.0129305.g004}

### Hemodynamic data--ScvO2, urinary output, lactate clearance, MAP, CVP {#sec017}

Forest plots of the presented data are available as Supporting Information ([S2 Fig](#pone.0129305.s002){ref-type="supplementary-material"}). Clinical and hemodynamic measurements at the beginning of the interventions, varied significantly between the trials ([S1 Table](#pone.0129305.s003){ref-type="supplementary-material"}). No vasopressor had a statistically significant effect of the MAP at any measurement point, compared to other vasopressor. CVP was higher with norepinephrine at the first measuring point compared to all other vasopressors by a mean of 0.84 mmHg (95% CI 0.16--1.51, I^2^ = 0%, n = 7). No vasopressor had a statistically significant effect on ScvO~2~ levels compared to other vasopressors, at any measurement point. Lactate levels in the first measuring point were lower with norepinephrine compared to vasopressin / terlipressin by a mean 0.23 mmol/l (95% CI 0.13--0.34, I^2^ = 0, n = 6). Compared to all other treatment, norepinephrine was not associated with decreased lactate levels at the first measuring point. No other effect on lactate levels was demonstrated with either comparison and by the pre-defined sensitivity analysis. Norepinephrine was associated with an increase in urine output compared to dopamine by a mean of 0.31 ml/kg/min (95% CI 0.12--0.49, I^2^ = 0%, n = 4). There were no other statistically significant results comparing urine output between other vasopressors. **Hemodynamic data---other measurements**

Forest plots of the presented data are available at Supporting Information ([S2 Fig](#pone.0129305.s002){ref-type="supplementary-material"}). Fourteen trials (43.5%) included only patients with high baseline CIX (defined as CIX \> 3.5 l/min/m^2^ by authors). At the first measuring point, CIX decreased with norepinephrine compared to dopamine by a mean of 0.35 l/min/m^2^ (95% CI 0.22--0.48, I^2^ = 18%, n = 7), to epinephrine by a mean of 0.87 l/min/m^2^ (95% CI 0.57--1.16, I^2^ = 0%, n = 4), and to all other vasopressors by a mean 0.7 l/min/m^2^ (95% CI 0.42--0.97, I^2^ = 42%, REM, n = 14). Heart rate was decreased with norepinephrine compared to dopamine in the first measuring point by a mean difference of 18.76 beats per minute (95% CI 9.76--27.76. I^2^ = 96%, REM, n = 8). When comparing norepinephrine to all other interventions, a decreased heart rate at the first measurement point of 8.92 beats per minute was noted (95% CI 1.6--16.23, I^2^ = 97%, REM, n = 19). One-hour SVRI measurements were higher with norepinephrine compared to dopamine and vasopressin / terlipressin by a mean difference of 192.82, 95% CI 60--325, I^2^ = 86%, REM, n = 8 and 196.56 (95% CI 4.4--3.88, I^2^ = 0%, n = 3, respectively).

Oxygen delivery index in the first measuring point were decreased with norepinephrine compared to other vasopressors by a mean of 14.06 ml/min/m^2^ (95% CI 0.16--27.9, I^2^ = 59%, REM, n = 10). First measuring point splanchnic CO~2~ difference was lower with norepinephrine in comparison to epinephrine by a mean difference of 3.74 (95% CI 1.82--5.66, I^2^ = 42%, REM, n = 4). There were insufficient data to compare vasopressors with regard to splanchnic blood flow and splanchnic oxygen delivery index.

Discussion {#sec018}
==========

The pooled evidence summarized in this meta-analysis shows absolute reduction of 11% in 28-days all-cause mortality with norepinephrine compared with dopamine corresponding to number needed to treat of 9. Dopamine resulted in more than twice the risk for major AEs including a twofold increase in the risk for cardiac arrhythmias. The hemodynamic profile of norepinephrine was also more favorable than the other vasopressors, resulting in decreased lactate levels, increased CVP and urine output in comparison to the other vasopressors. Further benefits of norepinephrine included reduced CIX and heart rate, elevated SVRI and reduced VIO~2~ and splanchnic CO~2~ difference.

We did not demonstrate mortality benefit with norepinephrine over epinephrine, phenylephrine and vasopressin / terlipressin or between the other comparisons, although a trend towards reduced mortality with norepinephrine was seen in all comparisons. Clinical outcomes other than mortality were seldom reported and therefore it was not possible to get strong evidence for length of ICU / hospital stay and ventilator / vasopressor free days. AEs were also reported only by 15/32 trials. The lower rates of cardiac arrhythmia and major AEs with norepinephrine compared to dopamine might account for the reduced mortality rates observed with norepinephrine.

Data regarding clinical and hemodynamic measurement were sparse and inconsistent in methodology and time of report. Although considered as targets for early goal directed therapy, most trials did not report on the variables included in the algorithm (including both studies that were published before and after 2004 with the publication of the surviving sepsis campaign \[[@pone.0129305.ref008]\]). The concept of early goal directed therapy was challenged recently in a large RCT \[[@pone.0129305.ref043]\], in which no mortality benefit with protocol based resuscitation was observed compared with usual care. Thus, obtaining the predefined hemodynamic goal with either vasopressor may not be translated to any clinical outcome change.

No statistically significant changes were observed between vasopressin / terlipressin and all adrenergic vasopressors (norepinephrine, dopamine) regarding mortality and AEs. One of the rationales for the use of non-adrenergic vasopressors is relative vasopressin deficiency in patients with septic shock \[[@pone.0129305.ref044]\] and the hypothesis that vasopressin can reduce the need for catecholamines and AEs associated with adrenergic stimulation. We did not observe a reduction in AEs, but most patients in the vasopressin arm received norepinephrine at randomization and at least for a part of the trial period as open-label vasopressor.

The use of vasopressors and inotropes for several conditions were addressed previously in systematic reviews and meta-analysis. A Cochrane systematic review \[[@pone.0129305.ref045]\] assessed the efficacy of vasopressors for the treatment of any circulatory failure in RCTs. The authors did not pool results for studies assessing septic patients alone. No mortality benefit was demonstrated for all direct comparisons between different vasopressors or vasopressor combinations. Dopamine was associated with more arrhythmias. Another review \[[@pone.0129305.ref046]\], focused only on the comparison of norepinephrine and dopamine in septic shock, but included observational studies as well as randomized controlled trials. It showed an advantage of norepinephrine over dopamine with regard to 28 days, all-cause mortality, RR for increased mortality with dopamine 1.12 (95% CI 1.01--1.20, I^2^ = 0%, n = 6). Vasu et al. \[[@pone.0129305.ref047]\] assessed norepinephrine and dopamine in septic shock, however the data quoted from the largest trial were inaccurate \[[@pone.0129305.ref015]\], thus introducing further bias.

Several limitations of this review should be noted. Included trials span a long period, starting before 1989 and the last published in 2012. During this period advances in support and early goal directed treatment had been introduced to improve the quality of care in ICU. However, mortality rates were unchanged from early to recent trials (weighted mean crude mortality rate 45.0%). We could not perform a meta-analysis of differences from baseline for the hemodynamic measures, which might be more easily interpreted than end values, because results were not reported as such. An individual patient data meta-analysis might provide a better understanding of the evidence accrued to date. To note, most of the trials were methodologically good or very good, however the treatment algorithm were different in regard to dosages, time to events and monitoring. The trials were diverse in reporting and statistical methods.

Future trials should use a uniformly acceptable protocol consisting of adequate methodological design, a common sepsis management algorithm (including the use of fluid resuscitation, stress dose steroids and initial hemodynamic targets). The reported outcomes should include all-cause mortality and, for patients discharged alive, length of hospital or ICU stay, length of ventilation, length of vasopressor support and AEs.

Conclusion {#sec019}
==========

These data supply further support for the use of norepinephrine over dopamine for the treatment of patients with septic shock in ICUs, given consistent reduced all-cause mortality at 28 days with supporting hemodynamic data and lower rate of major AEs and cardiac arrhythmias. This recommendation is based on data from all the RCTs published up to date, with no heterogeneity. Trials to guide recommendations for the use other vasopressors, especially non-adrenergic, are needed.

Supporting Information {#sec020}
======================

###### Funnel plot of norepinephrine vs dopamine primary outcome, Begg and Mazumdar rank correlation, Egger's regression intercept.

(DOCX)
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Click here for additional data file.

###### Forest plots (a-r).

**a,** Norepinephrine vs epinephrine, Mortality primary. **b,** Norepinephrine vs vasopressin OR terlipressin, Mortality primary. **c,** Norepinephrine vs phenylephrine, Mortality primary. **d,** Norepinephrine vs other, Mortality primary. **e,** Vasopressin / terlipressin vs other, Mortality Primary. **f,** Norepinephrine vs other, ICU (or hospital) stay. **g,** Norepinephrine vs other, 1st measurement point CVP. **h,** Norepinephrine vs vasopressin or terlipressin, 1st measurement point lactate. **i,** Norepinephrine vs dopamine, 1st measurement point urine output. **j,** Norepinephrine vs dopamine, 1st measurement point CIX. **k,** Norepinephrine vs epinephrine, 1st measurement point CIX. **l,** Norepinephrine vs other, 1st measurement point CIX. **m,** Norepinephrine vs dopamine, 1st measurement point heart rate. **n,** Norepinephrine vs other, 1st measurement point heart rate. **o,** Norepinephrine vs dopamine, 1st measurement point SVRI. **p,** Norepinephrine vs vasopressin or terlipressin, 1st measurement point SVRI. **q,** Norepinephrine vs other, 1st measurement point VIo2. **r,** Norepinephrine vs Epinephrine, 1st measurement point splanchnic CO2 difference.
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Click here for additional data file.

###### Hemodynamic data reported and baseline, first and second measurement points.
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Click here for additional data file.

###### List of excluded studies and reason for exclusion.
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Click here for additional data file.

###### PRISMA 2009 checklist.
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###### 

Click here for additional data file.
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